T1D Treatment Response Varies by Age, Stage, and Immune Biomarkers
For decades, type 1 diabetes management has followed a relatively uniform playbook. That paradigm is now under genuine…
For decades, type 1 diabetes management has followed a relatively uniform playbook. That paradigm is now under genuine…
A massive treatment gap exists between who qualifies for today's most transformative metabolic medicines and who…
For the millions living with sickle cell disease, cognitive decline and silent brain injury are devastating but poorly…
Everything we thought we knew about how the brain's command center is organized may need revision. For decades…
For patients whose cancers have stopped responding to chemotherapy or immunotherapy, the search for new…
For parents, clinicians, and public health professionals watching adolescent mental health deteriorate in real time, a…
Equal equipment availability doesn't mean equal access — and for women in economically disadvantaged neighborhoods…
For adults juggling multiple cardiovascular medications, the promise of a single daily pill replacing several has…
When a country's infant mortality rate barely budges over a decade despite near-universal medical attendance at death…
For millions of patients with treatment-resistant anemias, glucocorticoids represent a lifeline — yet physicians have…
For postmenopausal women — a demographic already navigating elevated cardiovascular and metabolic risk — the…
For the roughly 100,000 Americans living with pulmonary fibrosis, knowing whether a genetic mutation drives the…
For anyone tracking the future of implantable health monitors, the bottleneck has never been the sensor — it has been…
For the roughly one million Americans living with multiple sclerosis, treatment choice often hinges not just on…
For families managing children with catastrophic, drug-resistant epilepsies, treatment options have historically been…
One of the most stubborn problems in Alzheimer's therapeutics is that the disease attacks through multiple converging…
Semaglutide, the GLP-1R agonist best known for glycemic control and weight loss, alleviates osteoarthritis (OA)…
Among 208,155 bariatric surgery patients in a nationwide US cohort (2018–2025), 39,750 who subsequently received…
Long-term use of GLP-1 receptor agonists (semaglutide, liraglutide) and dual GIP/GLP-1 agonists (tirzepatide)…
In streptozotocin-induced diabetic male Sprague-Dawley rats, retatrutide — a triple GIP/GLP-1/glucagon receptor…
Get daily health research summaries delivered to your inbox.
Browse our synthesized research summaries by topic. We cover the latest findings from journals like Nature Medicine, The Lancet, Cell Metabolism, and 100+ other peer-reviewed sources.